Interferon Alfa and Interleukin-2 in Treating Patients With Metastatic Kidney Cancer

Status unconfirmed · Phase 2

Conditions studied: Kidney Cancer

In brief

RATIONALE: Biological therapies use different ways to stimulate the immune system to try to stop cancer cells from growing. Combining interferon alfa and interleukin-2 may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of interferon alfa and interleukin-2 in treating patients with metastatic kidney cancer.

Key facts

Study ID

NCT00002847

Run by

Blumenthal Cancer Center at Carolinas Medical Center

People needed

14

Starts

1995-09-01

Last updated by the study team

2013-12-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Blumenthal Cancer Center at Carolinas Medical Center — Charlotte, North Carolina, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.